DelMarPharmaceuticals 认领应用

VAL-083 is a small-molecule chemotherapeutic that benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved as a cancer therapy overseas. Efficacy has been demonstrated in a range of tumor types, including glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. Del Mar Pharma has filed an IND with the USFDA to initiate a dose-escalating Phase II clinical trial in refractory GBM, a major market opportunity.